[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370158-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370158-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","runx1-promotes-proliferation-of-cervical-cancer-through-tgfb2-mapk-pathway","RUNX1 promotes proliferation of cervical cancer through TGFB2-MAPK pathway","","Cervical cancer causes substantial mortality worldwide, and improved therapeutic targets are urgently needed. This study reports that RUNX1 is upregulated in cervical cancer and correlates with poor prognosis. Functional experiments show RUNX1 acts as an oncogene by accelerating the cell cycle and enhancing cell proliferation. Mechanistically, RUNX1 regulates the MAPK pathway via TGFB2 expression; inhibiting TGFB2 blocks MAPK activation and the proliferation induced by RUNX1. Integrated analyses also suggest an effect of RUNX1 on the tumor immune microenvironment through TGFB2. The findings indicate RUNX1 as a potential therapeutic target in cervical cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/runx1-promotes-proliferation-of-cervical-cancer-through-tgfb2-mapk-pathway/370158/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/runx1-promotes-proliferation-of-cervical-cancer-through-tgfb2-mapk-pathway/370158.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How is RUNX1 related to cervical cancer prognosis?","Question",{"text":63,"@type":64},"RUNX1 is upregulated in cervical cancer, and higher RUNX1 expression correlates with poor prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What functional role does RUNX1 play in cervical cancer cells?",{"text":68,"@type":64},"RUNX1 acts as an oncogene, accelerating cell cycle progression and promoting cell proliferation.",{"name":70,"@type":61,"acceptedAnswer":71},"How does RUNX1 influence the MAPK pathway?",{"text":72,"@type":64},"RUNX1 regulates the MAPK pathway by modulating TGFB2 expression, and TGFB2 inhibition impairs MAPK activation and RUNX1-driven proliferation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370158,1790334196,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRUNX1 promotes proliferation of cervical cancer throughTGFB2-MAPK pathway  \nYongqin Jia1, Neng Yang1, Shuai Tang1, Li Deng1, Yanzhou Wang1􀀍 & Xiongwei Cai2􀀍  \nAs cervical cancer (CC) caused more than 300,000 deaths in the world, it is urgent to identify therapeutic targets to improve survival. Though RUNX1 is overexpressed in CC, its specific role and underlying molecular mechanisms remain incompletely understood. Here we presented that RUNX1 was upregulated inCC and associated with poor prognosis. Functional studies demonstrated that RUNX1 acts as an oncogene in CC, with overexpression accelerating cell cycle progression and promoting cell proliferation. Mechanistically, RUNX1 regulates the MAPK pathway by modulating TGFB2 expression, while TGFB2 inhibition impaired MAPK pathway activation and the proliferation driven by RUNX1 overexpression. Comprehensive analyses also suggested that RUNX1 may modulate the immune microenvironment inCC throughTGFB2. These findings indicate that RUNX1 promotes CC progression by activating the MAPK pathway through upregulation of TGFB2. Our study provides new insights into the role of RUNX1 in CC proliferation and suggests RUNX1 as a potential therapeutic target in CC.  \nKeywords Cervical cancer, RUNX1, Proliferation, MAPK pathway, TGFB2, Immune microenvironment  \nCervical cancer (CC) is one of the most prevalent gynecologic malignancies, with incidence and mortality rates ranking fourth among gynecological cancer globally1. Currently, early-stage CC is treated primarily with radical hysterectomy and lymph node dissection, while advanced cases are managed with radiotherapy and cisplatinbased chemotherapy. Despite advancements in treatment, CC still results in 300,000 deaths worldwide each year2. It is well established that the initiation and progression of CC involve the activation of multiple oncogenes and the inactivation of tumor suppressor genes. However, many patients are diagnosed at advanced, often incurable stages, where surgical and chemoradiotherapy outcomes remain sub-optimal3. Therefore, identifying effective therapeutic targets is crucial for understanding underlying CC progression and improving patient prognosis.  \nRUNX1(Runt-related transcription factor 1), also known as acute myeloid leukemia 1, is located on chromosome 21 in humans, and is one of the members of RUNX family of transcription factors, which includes RUNX1, RUNX2, and RUNX34. Previous studies have identified that RUNX1 as one of the most frequently mutated genes in hematological malignancies, where it often functions as tumor suppress or, particularly in acute leukemia5. RUNX1 is also aberrantly expressed in various solid tumors, with elevated expression observed in colorectal cancer6, glioma, migration, and immunotherapy7, pancreatic cancer8, and clear cell renal cell carcinoma9, and reduced expression in gastric cancer10. Notably, the role ofRUNX1 in these tumors is contextdependent, modulating cancer cell proliferation, metastasis, angiogenesis, and stemness either directly or indirectly11. Although upregulation is still unclear.  \nThe mitogen activated protein kinase (MAPK) signaling pathway is closely related to tumor initiation and progression12, playing a key role in regulating cell proliferation, apoptosis, invasion, metastasis and angiogenesis13. In several cancer types, RUNX1 exerts biological functions by activating the MAPK pathway. For instance, in glioma, RUNX1 promotes metastasis and angiogenesis by activating the P38 MAPK signaling pathway14; in lung cancer, RUNX1 enhances tumor progression by regulating ACP5 expression to activate MAPK pathway. Our previous research indicated that K562 cells harboring RUNX1 mutations are more sensitive to AraC following MAPK pathway inhibition15. The high expression of RUNX1 in CC suggests that it may contribute to CC progression, potentially by inducing CC cell proliferation through re","cbCaitqUTCwLIiT3","https://ap.wps.com/l/cbCaitqUTCwLIiT3","pdf",12465120,13,"English","# RUNX1 and cervical cancer background\n## Clinical treatment and prognosis\n## RUNX1 features and tumor context\n## MAPK pathway and prior evidence","[{\"question\":\"How is RUNX1 related to cervical cancer prognosis?\",\"answer\":\"RUNX1 is upregulated in cervical cancer, and higher RUNX1 expression correlates with poor prognosis.\"},{\"question\":\"What functional role does RUNX1 play in cervical cancer cells?\",\"answer\":\"RUNX1 acts as an oncogene, accelerating cell cycle progression and promoting cell proliferation.\"},{\"question\":\"How does RUNX1 influence the MAPK pathway?\",\"answer\":\"RUNX1 regulates the MAPK pathway by modulating TGFB2 expression, and TGFB2 inhibition impairs MAPK activation and RUNX1-driven proliferation.\"}]","RUNX1 promotes proliferation of cervical cancer through TGFB2-MAPK pathway | PDF",1790187109,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad6bb12486eca557d99f36c0c0399731.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0122969419461db0779f52d67261deb.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e88be58e2c83c5ec7aa568e2863665cf.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94eb56390d88371b956d225b831f64a6.webp",980,1287]